GFAP and myeloid sarcoma: The level of GFAP in blood is considered to reflect the quantity of reactive astrocytosis in the central nervous system (CNS).1 Serum soluble glial fibrillary acidic protein (sGFAP) is considered a promising biomarker for multiple sclerosis (MS) disease progression.2,3